Literature DB >> 32647434

Hematopoietic Stem Cell Transplantation for Fanconi Anemia: A Single Center Experience from India.

Divya Doval1, Dharma Choudhary1, Sanjeev Kumar Sharma1, Vipin Khandelwal1, Meet Kumar1, Anil Handoo2, Rasika Setia3.   

Abstract

Hematopoietic stem cell transplantation (HSCT) is the only treatment option for the hematological manifestations of Fanconi anemia (FA). Fludarabine based reduced intensity conditioning regimens have helped in improving outcomes significantly in FA patients. We retrospectively analyzed the outcomes of FA patients who underwent allogeneic HSCT at BLK Superspeciality Hospital, New Delhi from June 2011 to September 2019. Twenty FA patients underwent 23 transplants at our center. Overall survival and disease free survival were 65% and 50%, respectively at a median of 23 months. Overall mortality was 30%. HSCT for FA is a feasible option even in developing countries although children present late to transplant centers after multiple transfusions and infections. © Indian Society of Hematology and Blood Transfusion 2020.

Entities:  

Keywords:  Fanconi anemia; HSCT; Matched sibling donor

Year:  2020        PMID: 32647434      PMCID: PMC7326841          DOI: 10.1007/s12288-020-01254-3

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  9 in total

Review 1.  Hematopoietic cell transplantation in Fanconi anemia: current evidence, challenges and recommendations.

Authors:  Christen L Ebens; Margaret L MacMillan; John E Wagner
Journal:  Expert Rev Hematol       Date:  2016-12-21       Impact factor: 2.929

2.  Four decades of stem cell transplantation for Fanconi anaemia in the Netherlands.

Authors:  Stephanie E Smetsers; Frans J Smiers; Dorine Bresters; Martine C Sonnevelt; Marc B Bierings
Journal:  Br J Haematol       Date:  2016-07-29       Impact factor: 6.998

3.  Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia.

Authors:  John E Wagner; Mary Eapen; Margaret L MacMillan; Richard E Harris; Ricardo Pasquini; Farid Boulad; Mei-Jie Zhang; Arleen D Auerbach
Journal:  Blood       Date:  2006-10-12       Impact factor: 22.113

4.  HLA-matched related-donor HSCT in Fanconi anemia patients conditioned with cyclophosphamide and fludarabine.

Authors:  Lina Benajiba; Clementine Salvado; Jean-Hugues Dalle; Charlotte Jubert; Claire Galambrun; Jean Soulier; Gerard Socié; Regis Peffault de Latour
Journal:  Blood       Date:  2015-01-08       Impact factor: 22.113

Review 5.  Hematopoietic cell transplantation in Fanconi anemia and dyskeratosis congenita: A minireview.

Authors:  Mouhab Ayas
Journal:  Hematol Oncol Stem Cell Ther       Date:  2017-06-15

Review 6.  Haematopoeitic cell transplantation for Fanconi anaemia - when and how?

Authors:  Margaret L MacMillan; John E Wagner
Journal:  Br J Haematol       Date:  2010-02-05       Impact factor: 6.998

Review 7.  Fanconi anemia and its diagnosis.

Authors:  Arleen D Auerbach
Journal:  Mutat Res       Date:  2009-02-28       Impact factor: 2.433

8.  The outcome of children with Fanconi anemia given hematopoietic stem cell transplantation and the influence of fludarabine in the conditioning regimen: a report from the Italian pediatric group.

Authors:  Franco Locatelli; Marco Zecca; Andrea Pession; Giuseppe Morreale; Daniela Longoni; Paolo Di Bartolomeo; Fulvio Porta; Franca Fagioli; Bruno Nobili; Maria Ester Bernardo; Chiara Messina
Journal:  Haematologica       Date:  2007-10       Impact factor: 9.941

9.  Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience.

Authors:  Régis Peffault de Latour; Raphael Porcher; Jean-Hugues Dalle; Mahmoud Aljurf; Elisabeth T Korthof; Johanna Svahn; Roelof Willemze; Cristina Barrenetxea; Valerie Mialou; Jean Soulier; Mouhab Ayas; Rosi Oneto; Andrea Bacigalupo; Judith C W Marsh; Christina Peters; Gerard Socie; Carlo Dufour
Journal:  Blood       Date:  2013-10-21       Impact factor: 22.113

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.